Statin therapy initiation after index revascularization in patients with peripheral arterial occlusive disease was associated with significant reductions in mortality and cardiovascular events.
The addition of evolocumab to a statin regimen was found to lower the risk for complex coronary disease requiring revascularization in patients with stable atherosclerosis.
The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.
Coronary revascularization with a bilateral internal thoracic artery approach was found to increase the risk for post-operative acute lower limb ischemia in patients with peripheral artery disease.
Gout was not found to be associated with increased risk for cardiovascular complications in patients with peripheral artery disease.
The Sentinel cerebral protection system was associated with a lower incidence of ischemic stroke and in-hospital mortality in patients undergoing TAVR.
A substantial percentage of women with peripheral artery disease reported having depressive symptoms.
Individuals of Hispanic/Latino background with known peripheral artery disease (PAD) have the lowest use of all classes of cardiovascular medications.
Researchers identified evidence trough a literature review for risk assessment, testing, and optimal medical therapy to reduce perioperative cardiovascular risk prior to noncardiac surgery.
Patients with peripheral artery disease were found to have lower statin use compared with patients with coronary heart disease or cerebrovascular conditions.
